Published: 17-04-2024 12:26 | Updated: 17-04-2024 12:27

Welcome Mattias Carlsten - new research group leader at Labmed

Group photo of Mattias Carlsten research group
Mattias Carlsten research group. From left: Filip Segerberg, Agneta Andersson, Caroline Eriksson, Laura Sanz, Marta Merlo, Mattias Carlsten. Photo: N/A

On April 1, Mattias Carlsten and his research group moved from Department of Medicine, Huddinge (MedH) to the Department of Laboratory Medicine (Labmed).

Mattias Carlsten’s research focuses on reprogramming immune cells, primarily natural killer (NK) cells, to enhance their ability to locate and eliminate cancer within the body. 

– The goal is to develop new more efficient therapies for cancer and explore them in patients. As part of the goal, we hope to develop new cell therapies with less side effects, says Mattias.

The group works with Advanced Therapy Medicinal Products (ATMP).

– The most exciting aspect is the rapid positive development in the field of ATMP. However, there are challenges associated with this rapid progress, such as how to develop and produce these treatments, as well as how society, healthcare, and regulatory agencies should adapt to the swift advancements.

About the move to ANA Futura

– My team and I are really looking forward to working in the dynamic research environment at ANA Futura. We are excited to be part of its growth and future. Having worked extensively in the ATMP arena, it feels natural to contribute significantly here at ANA Futura, not only from a basic research perspective but also in my role as a physician, clinical investigator in ATMP, and research lead for the clinical unit focused on cell therapy and allogeneic stem cell transplantation (CAST) at the hospital.

When Mattias isn’t working, he wishes the days were longer.

– I have many hobbies, but unfortunately not enough time to pursue them all. I enjoy sports, sailing, and fishing. A couple of years ago, we bought a house, and I find pleasure in working on it and tending to the garden.